What antipsychotic medication and dosing regimen is recommended for a post‑stroke patient experiencing agitation or psychosis?

Antipsychotic Management for Post-Stroke Patients

For post-stroke patients with agitation or psychosis, quetiapine is the preferred antipsychotic because it carries significantly lower mortality risk than haloperidol or risperidone in elderly stroke survivors, and should be initiated at 12.5–25 mg twice daily (maximum 200 mg twice daily). 1

First-Line Antipsychotic Selection

• Quetiapine is the safest choice in post-stroke elderly patients, demonstrating lower one-year all-cause mortality compared to both haloperidol (adjusted hazard ratio [aHR] = 1.22) and risperidone (aHR = 1.31) in a large nationwide cohort study of over 59,000 stroke patients. 1

• Start quetiapine at 12.5–25 mg twice daily, titrating gradually to a maximum of 200 mg twice daily (400 mg/day total). 2

• Quetiapine is more sedating and can cause transient orthostatic hypotension, requiring blood pressure monitoring during titration. 2

Critical Dosing Thresholds to Avoid Excess Mortality

• Keep doses below 0.5 defined daily dose (DDD) when using haloperidol or risperidone, as doses exceeding this threshold significantly increase mortality risk in post-stroke elderly patients. 1

• If haloperidol is used despite higher mortality risk, the maximum dose should not exceed 4–6 mg per day in elderly patients to minimize extrapyramidal and cardiovascular adverse effects. 2

• If risperidone is selected, use 0.5–1 mg twice daily (maximum 2–3 mg/day total), as doses ≥2 mg/day substantially increase extrapyramidal symptom risk. 2, 3

Alternative Second-Line Options

• Olanzapine 5 mg twice daily (maximum 10 mg/day) may be considered if quetiapine is ineffective or not tolerated, though it has the worst cardiometabolic profile among antipsychotics and requires adjunctive metformin plus intensive metabolic monitoring. 2

• Olanzapine produces less QTc prolongation (2 ms) than quetiapine (6 ms) and is generally well tolerated. 2, 3

Acute Agitation Management

• For breakthrough severe agitation requiring rapid control, lorazepam 1–2 mg IM/IV is at least as effective as haloperidol and carries lower extrapyramidal symptom risk. 2, 4

• Ziprasidone 20 mg intramuscular provides rapid agitation control within 15–30 minutes with minimal extrapyramidal symptoms and superior tolerability compared to haloperidol. 2, 5

• However, ziprasidone should be avoided in stroke patients with QTc prolongation, cardiac disease, electrolyte disturbances, or concomitant QTc-prolonging medications due to moderate QTc prolongation (5–22 ms). 2

Duration of Treatment

• Post-stroke psychosis may require long-term low-dose maintenance therapy in certain patients, particularly those with non-acute onset and persistent symptoms. 6

• A case report demonstrated that post-stroke psychosis initially controlled with risperidone 3 mg/day required continuous maintenance at 0.25 mg/day after symptoms recurred within one week of full discontinuation. 6

• Before initiating antipsychotics, discuss with the patient (if feasible) and surrogate decision-makers that treatment goals, duration, and potential need for long-term therapy will depend on symptom response. 7

Treatment Monitoring and Titration

• Assess response within 5–7 days; if inadequate, increase the dose by the initial increment. 2

• A full therapeutic trial requires 4–8 weeks before concluding efficacy. 2

• Use a quantitative measure (e.g., standardized agitation scale) to track symptom severity and treatment response. 7, 2

• If there is no clinically significant response after a 4-week trial at adequate dose, taper and withdraw the antipsychotic. 7

Baseline and Ongoing Monitoring

• Before initiating antipsychotics, obtain baseline BMI, waist circumference, blood pressure, HbA1c, fasting glucose, lipid panel, prolactin, liver and renal function tests, CBC, and ECG. 2

• Repeat fasting glucose at 4 weeks; repeat all metabolic parameters at 3 months and annually thereafter. 2

• Baseline ECG is essential in stroke patients given their elevated cardiovascular risk and the QTc-prolonging effects of most antipsychotics. 2

Critical Pitfalls to Avoid

• Never combine two atypical antipsychotics (e.g., olanzapine + quetiapine), as this provides no evidence of superior efficacy and dramatically increases adverse-effect burden including respiratory depression, anticholinergic toxicity, and metabolic complications. 2

• Avoid anticholinergic agents (benztropine, trihexyphenidyl) for extrapyramidal symptoms in agitated patients, as they paradoxically increase agitation. 2

• Do not use high-dose benzodiazepines (e.g., diazepam >10 mg/day) concurrently with antipsychotics, as this combination markedly increases respiratory depression risk, especially in elderly stroke patients. 2

• Regular benzodiazepine use leads to tolerance, addiction, depression, cognitive impairment, and paradoxical agitation in ~10% of patients; prescribe infrequently at low doses of short-half-life agents only. 2

Non-Pharmacological Interventions

• Review the clinical response to non-pharmacological interventions (environmental modifications, behavioral strategies, person-centered care) before initiating antipsychotic medication for non-emergency situations. 7

• Antipsychotic medication should only be used when symptoms are severe, dangerous, and/or cause significant distress to the patient. 7

• Assess for pain and other potentially modifiable contributors (infection, constipation, medication side effects) that may be driving agitation or psychosis. 7